Download The Validation of J-CAPRA Risk Assessment for Prostatic Cancer in

The Validation of J-CAPRA Risk Assessment for Prostatic Cancer in Our Cancer Registry
Introduction and Objectives: The Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score was
developed to assess the risk of disease progression among prostate cancer patients receiving primary
androgen deprivation therapy (PADT) at the time of diagnosis by using the Japan Study Group of
Prostate Cancer (J-CaP) database and the Cancer of the Prostate Strategic Urologic Research Endeavor
(CaPSURE) registry. We validated the J-CAPRA score in our prostate cancer registry.
Materials and Methods: We have diagnosed and treated 355 prostate cancer patients between 1995
and 2011, who underwent primary radical prostatectomy (OP), radiation therapy (RT), PADT or watchful
waiting (WW). Multiple logistic regression analysis was used to assess progression risk on the basis of
clinical data available at diagnosis, prostate-specific antigen level (PSA), Gleason score (GS), clinical
tumor stage (STAGE), the age at diagnosis (AGE), primary treatment and/or the J-CAPRA score.
Results: primary treatment (p<0.001), STAGE (p<0.001), GS (p<0.001) and J-CAPRA score (p<0.001)
were factors associated with disease progression. Statistical significance was found in PADT vs OP
(p<0.001, odds ratio 15.655), WW vs OP (p<0.001, odds ratio 88.09), GS 7 vs GS≦6 (p=0.008, odds
ratio 4.746), GS≧8 vs GS≦6 (p<0.001, odds ratio 9.464), STAGE D vs B (P<0.001, odds ratio 11.032),
J-CAPRA intermediate risk vs low risk (p<0.001) and high risk vs low risk (p<0.001, odds ratio 36.807).
AGE was not a factor associated with disease progression. The model with primary treatment, STAGE
and GS was fitter for the risk assessment than the model with primary treatment and J-CAPRA score.
Conclusion: J-CAPRA score was applicable not only for PADT patients but all patients. The risk
assessment with primary treatment, STAGE and GS was more suitable than with primary treatment and
J-CAPRA score in our cases.